板块持续跑赢大盘，关注后续创新药催化（附CD73靶点研究）（2025.06.03-2025.06.08）

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualan Biological Engineering-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a 1.13% increase, surpassing the CSI 300 index by 0.25 percentage points. The focus is on the potential of innovative drugs and the CD73 target in cancer immunotherapy [5][26]. - CD73 is highlighted as a promising target for tumor immunotherapy, with several products in clinical research stages, including small molecules and monoclonal antibodies [4][21]. Summary by Sections Industry Investment Rating - The report recommends a "Buy" for companies such as Junshi Bioscience, Hualan Biological Engineering-B, and others, indicating strong potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector has shown a 1.13% increase, outperforming the CSI 300 index by 0.25 percentage points. Sub-sectors like innovative drugs and vaccines performed well, while traditional Chinese medicine and blood products lagged [32][40]. Company Dynamics - Companies like Lepu Medical and Sunshine Nuohua have made significant announcements regarding product approvals and clinical trials, indicating active development in the sector [33][36]. Industry Trends - The report emphasizes the importance of the CD73 target in cancer treatment, with several leading candidates in clinical trials, including ATG-037 and Oleclumab, which are showing promising early results [21][25].